10-Q · May 7, 2026
Shattuck Labs reported zero revenue for Q1 2026, resulting in a net loss of $14.8 million, or $0.13 per share, which reflects a narrower loss compared to $13.7 million, or $0.27 per share, from the prior year. Cash and…
Earnings analysis · 10-Q
STTK earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied extract contains no quarterly income statement, balance-sheet, cash-flow, segment, or MD&A financial data, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the filing…
Read full summary
The supplied extract contains no quarterly income statement, balance-sheet, cash-flow, segment, or MD&A financial data, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the filing text provided. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors from the 2025 Form 10-K. The principal incremental item is a director’s potential sale of up to 71,083 shares under a Rule 10b5-1 plan.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Rated Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No Equity Issuance or Buybacks
The filing reports no unregistered securities sales and no issuer share repurchases during the period; both were reported as “None.”
What to watch
-
Potential Insider Share Sales
A Rule 10b5-1 plan adopted by director Dr. Neil Gibson provides for potential sales of up to 71,083 common shares and expires no later than February 26, 2027, subject to conditions.
-
Risk Factors Unchanged
The company states there were no material changes to the risk factors disclosed in its 2025 Form 10-K, limiting the filing’s update on company-specific risks.
Management's outlook
The supplied 10-Q extract does not provide quantitative revenue or EPS guidance. No outlook, liquidity outlook, or capital-spending forecast was disclosed in the provided text.
Earlier filings 4
10-K · March 5, 2026
Shattuck Labs positions itself as a clinical-stage immunology biotech developing potentially first-in-class DR3 blocking antibodies, led by SL-325 (1.3 picomolar DR3 affinity). The company reports positive IND‑enabling…
10-Q · May 1, 2025
Shattuck Labs reported Q1 2025 collaboration revenue of $0 versus $1,115 in Q1 2024, driving total revenue to zero. Net loss narrowed to $13,702 (EPS -$0.27) from $18,504 (EPS -$0.37) year-over-year, with lower R&D…
10-K · March 27, 2025
Shattuck Labs positions itself as a developer of first-in-class DR3 antagonist biologics led by SL-325, which it expects to file an IND in the third quarter of 2025 and complete Phase 1 enrollment in the second quarter…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.